Swiss - Delayed Quote CHF

Kuros Biosciences AG (KURN.SW)

25.92

-1.28

(-4.71%)

At close: June 13 at 5:31:20 PM GMT+2

Kuros Biosciences to share latest MagnetOs™ market impact and strategic priorities at Capital Market Day in Zürich

Kuros Biosciences to share latest MagnetOs™ market impact and strategic priorities at Capital Markets Day in Zürich Schlieren (Zürich), Switzerland, May 13, 2025 – Kuros Biosciences (“Kuros” or the “Company”) a leader in innovative biologic technologies, is pleased to announce today’s Capital Markets Day on Tuesday, May 13, 2025, at 9am CEST, at the Hyatt Regency Zürich Airport, The Circle, Zürich, Switzerland. The event will also be available virtually via live webcast. Capital Markets Day will

GlobeNewswire last month

CSBTF
Annual General Meeting of Kuros Biosciences approves all resolutions

Annual General Meeting of Kuros Biosciences approves all resolutions Schlieren (Zurich), Switzerland, April 15, 2025 – Kuros Biosciences (“Kuros” or the “Company”) a leader in next generation bone healing technologies, held its Annual General Meeting today. The Annual General Meeting approved the Annual Report, the Annual Financial Statements, and the Consolidated Financial Statements for the year 2024 and took note of the Reports of the Auditors. Shareholders granted discharge to the Board and

GlobeNewswire last month

CSBTF
Kuros Biosciences reports 82% year over year increase in sales in the first three months of 2025

Ad hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences reports 82% year over year increase in sales in the first three months of 2025 Financial & Operational Highlights Direct MagnetOs™ sales increased by 79% to USD 28.4 million in Q1 2025 (Q1 2024: USD 15.8 million)Total Medical Device sales rose by 82% to USD 28.8 million (Q1 2024: USD 15.8 million) with monthly revenue surpassing USD 10.0 million for the first timeTotal Group EBITDA reached USD 2.0 million (Q1 2

GlobeNewswire last month

CSBTF
Kuros Biosciences grows sales to CHF 75.6 million for 2024

Ad-hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences grows sales to CHF 75.6 million for 2024 Financial Highlights Direct MagnetOs™ sales increased by 136% to CHF 74.8 million (2023: CHF 31.7 million)Total Medical Device sales rose by 125% to CHF 75.6 million (2023: CHF 33.6 million)Total Group EBITDA reached CHF 2.2 million (2023: EBITDA loss of CHF (5.9) million), including the impairment, the group ended in a net loss of CHF (4.3) millionTotal Group adjusted E

GlobeNewswire 3 months ago

CSBTF
Kuros Biosciences USA, Inc. Announces an Exclusive Strategic Agreement with the Medtronic Spinal Division

Kuros Biosciences USA Inc., ("Kuros"), a wholly owned subsidiary of Kuros Biosciences AG, a global leader in advanced musculoskeletal bone healing technologies, today announced a strategic five-year, exclusive sales agency agreement with Medtronic, ...

ACCESS Newswire 5 months ago

CSBTF
Kuros Biosciences Expands into Extremities Markets

Commercial Highlights Appointment of Jantzen Cole as Vice President of Market Development, Extremities, to drive the Company's acceleration beyond the spine market Strategic expansion opens new addressable market opportunity estimated at $1 billion ...

ACCESS Newswire 6 months ago

CSBTF
Kuros Reports 149% Increase in Direct MagnetOs Sales and Exceeds Cash Flow Breakeven in the First Nine Months of 2024

Financial Highlights Direct MagnetOsTM sales rose by 149% to CHF 50.6 million in the first nine months of 2024, from CHF 20.4 million in the same period in 2023 Total Kuros Medical Devices segment sales accelerated to CHF 51.1 million in Q3 2024 from ...

ACCESS Newswire 7 months ago

CSBTF
Kuros Biosciences Reports First Half of 2024 Results

Financial Highlights Direct MagnetOs™ sales increased by 159% to CHF 31.6 million from CHF 12.2 million in H1 2023; this corresponds to a sequential increase of 62% or CHF 12.1 million over H2 2023 Total Kuros Medical Devices segment sales increased ...

ACCESS Newswire 10 months ago

CSBTF
Kuros Biosciences Announces Peer-Reviewed Publication of MagnetOs MAXA Level 1 Study Outcomes in Spine, Indicating Superiority Over Autograft

ZURICH, SWITZERLAND / ACCESSWIRE / June 25, 2024 / Kuros Biosciences, a leader in next generation bone healing technologies, today announced the publication of a peer-reviewed manuscript that details the clinical data of its MAXA Level 1 prospective, ...

ACCESS Newswire 11 months ago

CSBTF

Performance Overview

Return	KURN.SW	MSCI WORLD (^990100-USD-STRD)
YTD	+21.41%	+4.89%
1-Year	+107.36%	+10.94%
3-Year	+1,236.08%	--

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Kuros Biosciences AG (KURN.SW)

Kuros Biosciences to share latest MagnetOs™ market impact and strategic priorities at Capital Market Day in Zürich

Annual General Meeting of Kuros Biosciences approves all resolutions

Kuros Biosciences reports 82% year over year increase in sales in the first three months of 2025

Kuros Biosciences grows sales to CHF 75.6 million for 2024

Kuros Biosciences USA, Inc. Announces an Exclusive Strategic Agreement with the Medtronic Spinal Division

Kuros Biosciences Expands into Extremities Markets

Kuros Reports 149% Increase in Direct MagnetOs Sales and Exceeds Cash Flow Breakeven in the First Nine Months of 2024

Kuros Biosciences Reports First Half of 2024 Results

Kuros Biosciences Announces Peer-Reviewed Publication of MagnetOs MAXA Level 1 Study Outcomes in Spine, Indicating Superiority Over Autograft

Performance Overview